Company 4 Zydus Lifesciences brings SEMAGLYNTM, MASHEMATM, and ALTERMET Zydus Lifesciences has introduced its generic version of semaglutide injection under the brand names SEMAGLYNTM, MASHEMATM, and ALTERMET
Dementia, stroke, and survival A 2025 JAMA Network Open analysis of nearly 61,000 adults with type 2 diabetes and obesity found GLP-1 users had a ~37% lower risk of dementia, ~19% lower risk of stroke, and ~30% lower all-cause mortality than people on other diabetes drugs
Provider review (same day in most cases): A board-certified provider reviews your intake, often within one to four hours
Two minutes feels much longer than you expect when you have liquid pooled under your tongue
Your health care professional should show you how to take Ozempic before you use it for the first time
LncRNA SNHG7/miR-181b-5p/TLR4 activates inflammation and promotes pyroptosis through NF-kappaB signaling in diabetic nephropathy